



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Elbasvir

Cat. No.:	HY-15789
CAS No.:	1370468-36-2
Molecular Formula:	C ₄₉ H ₅₅ N ₉ O ₇
Molecular Weight:	882.02
Target:	HCV
Pathway:	Anti-infection
Storage:	Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year



SOLVENT & SOLUBILITY

In Vitro

DMSO : ≥ 50 mg/mL (56.69 mM)
 * "≥" means soluble, but saturation unknown.

	Solvent Concentration	Mass	1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM		1.1338 mL	5.6688 mL	11.3376 mL
	5 mM		0.2268 mL	1.1338 mL	2.2675 mL
	10 mM		0.1134 mL	0.5669 mL	1.1338 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
 Solubility: ≥ 2.5 mg/mL (2.83 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

Elbasvir (MK-8742) is a hepatitis C virus nonstructural protein 5A (HCV NS5A) inhibitor with EC₅₀s of 4, 3 and 3 nM against genotype 1a, 1b, and 2a, respectively.

IC₅₀ & Target

EC₅₀: 4 nM (HCV 1a), 3 nM (HCV 1b), 3 nM (HCV 2a)^[1]

In Vitro

Elbasvir shows potent activity against genotype 1a and 1b replicons, with EC₉₀ of 0.006 nM for both the wild-type 1a_H77 and 1b_con1 replicons. Elbasvir inhibits genotype 3 replicons with EC₉₀ of 0.12 nM. Elbasvir (0.06 nM, 0.6 nM, and 6 nM) demonstrates dose-dependent suppression of resistant genotype 1a replicons, illustrated by the reductions in colony counts at higher doses^[1]. Elbasvir is highly potent against HCV replicons bearing NS5A sequences from GT1a, -1b, -2a(31L), -3a, -4a, -5a, and -6, with EC₅₀s in the low-picomolar range^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CUSTOMER VALIDATION

- Adv Sci (Weinh). 2022 Oct 18;e2203088.
- Hepatology. 2019 May;69(5):1861-1872.
- J Gastroenterol. 2019 May;54(5):449-458.
- Viruses. 2018 Aug 28;10(9). pii: E462.
- Pharmaceuticals. 2022 Feb 18;15(2):242.

See more customer validations on www.MedChemExpress.com

REFERENCES

- [1]. Liu R, et al. Susceptibilities of genotype 1a, 1b, and 3 hepatitis C virus variants to the NS5A inhibitor Elbasvir. Antimicrob Agents Chemother. 2015 Nov;59(11):6922-6929.
- [2]. Lahser FC, et al. The Combination of Grazoprevir, a Hepatitis C Virus (HCV) NS3/4A Protease Inhibitor, and Elbasvir, an HCV NS5A Inhibitor, Demonstrates a High Genetic Barrier to Resistance in HCV Genotype 1a Replicons. Antimicrob Agents Chemother. 2016 A
-

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA